10 assets in Human Papilloma Virus Infection

Therapeutic assets addressing Human Papilloma Virus Infection, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Gardasil 9 Vaccine Human Papilloma Virus Infection	Eunice Dube	P4	BBB (76)
Human Papillomavirus Serotype 58 Whole Human Papilloma Virus Infection	Beijing Health Guard Biotechnology, Inc	P3	BB (70)
Recombinant Nonavalent Human Papillomavirus Vaccine Human Papilloma Virus Infection	Beijing Health Guard Biotechnology, Inc	P3	BB (70)
Hepatitis B Virus Vaccine Human Papilloma Virus Infection	Eunice Dube	P4	BB (65)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Human Papilloma Virus Infection	National Cancer Institute (NCI)	P2	CCC (54)
9-valent human papillomavirus recombinant vaccine Human Papilloma Virus Infection	University Health Network, Toronto	P2	CCC (53)
Entinostat Human Papilloma Virus Infection	National Cancer Institute (NCI)	P1/2	CCC (48)
pds01adc Human Papilloma Virus Infection	National Cancer Institute (NCI)	P1/2	CCC (48)
Star0602 Human Papilloma Virus Infection	Marengo Therapeutics, Inc.	P1/2	CCC (48)
pds0101 Human Papilloma Virus Infection	Weill Medical College of Cornell University	P2	NR ()